China (Mainland)
MDV 3100 CAS NO.915087-33-1
- Min.Order: 1 Gram
- Payment Terms:
- Product Details
Keywords
- 4-(3-(4-Cyano-3-(trifluoromethyl)phenyl)-5,5-dimethyl-4-oxo-2-thioxoimidazolidin-1-yl)-2-fluoro-N-me
- Enzalutamide
- androgen receptor antagonist
Quick Details
- ProName: MDV 3100
- CasNo: 915087-33-1
- Molecular Formula: C21H16F4N4O2S
- Appearance: white powder
- Application: Enzalutamide (marketed as Xtandi and f...
- ProductionCapacity: Metric Ton/Day
- Purity: 95%
- LimitNum: 1 Gram
Superiority
HIgh Quality
Details
Enzalutamide (marketed as Xtandi formerly known as MDV3100) is an androgen receptor antagonist drug developed by the pharmaceutical company Medivation fthe treatment of metastatic castration-resistant prostate cancer.[1] Medivation has reported up to an 89% decrease in prostate specific antigen serum levels after a month of taking the medicine.[2]Early preclinical studies also suggest that enzalutamide inhibits breast cancer cell growth.[3][4] In August of 2012, theU.S. Food Drug Administration approved enzalutamide fthe treatment of castration-resistant prostate cancer.
